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Insulinomas are rare functional neuroendocrine tumours. These tumours present with symptoms of hypoglycaemia, adrenergic
and neuroglycopenic symptoms. Insulinomas are usually small in size, making them difficult to locate. Diagnosis is often delayed
in these cases resulting in lasting neurological complications, often not reversible after surgical removal of the insulinoma. We
report a case of a 33-year-old HIV-positive female with delayed presentation of an insulinoma. She presented with a long history
of neurological symptoms with lasting neurological sequelae and poor functional status, during which time the diagnosis of
insulinoma was repeatedly missed.
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Introduction
Insulinoma is one of the functional pancreatic tumours derived
from the pancreatic ductal/acinar system that is rare but often
missed.1 Patients typically present with symptoms of unpro-
voked hypoglycaemia but as these symptoms are non-specific
diagnosis is often delayed due to late presentation of patients
or failure of healthcare workers to recognise the disease early.
The main clinical features include adrenergic symptoms such
as sweating and palpitations and neuroglycopenic symptoms
including confusion, anxiety, stupor, convulsions and coma.
The neuroglycopenic symptoms are often misdiagnosed as
primary neurological disorders, which often causes a delay in
diagnosis and treatment that can result in permanent neurologi-
cal damage. Insulinomas are usually small in size and benign in
nature. The tumours are malignant in less than 10% of cases.2
Insulinomas are commonly sporadic in nature with only a few
cases described as being associated with genetic mutations.2
Localisation of these tumours presents a challenge to most clin-
icians as the standard techniques often used for localisation
have poor sensitivity and specificity. Here we present a case of
a patient who presented with recurrent hypoglycaemia compli-
cated by neurological sequelae.
Case report
History
A 33-year-old female was referred to the Charlotte Maxeke
Johannesburg Academic hospital from a care centre for assess-
ment of her cognitive dysfunction and limb weakness. On
arrival at the emergency room she was documented to have
severe hypoglycaemia with a laboratory glucose of 1.3 mmol/l.
She was not able to provide a history due to her poor cognitive
function, but her family reported a one-year history of recurrent
admissions to hospitals for hypoglycaemia. When given a
glucose infusion she had clinical improvement post-incident
and did not have further investigation done to ascertain the
cause. She also had a history of difficulty walking progressively
worsening associated with difficulty speaking, but no urinary
or faecal incontinence and no sensory symptoms. She did not
have a history of seizures.
On physical examination, she had frontal release signs, ataxic
speech, wasting of upper and lower limbs with clawing of
both hands and feet with generalised hypotonia and hypore-
flexia. Her abdominal examination was normal.
Laboratory investigation (Table 1) confirmed hypoglycaemia
with a glucose of 1.3 mmol and with non-suppressed insulin
of 23.8 mIU/l and C-peptide of 3 mg/l measured at the same
time. Her serum cortisol level was 778 nmol/l excluding hypo-
cortisolaemia as a cause for hypoglycaemia. Her thyroid func-
tion tests were normal as was her renal function (urea
2.3 mmol/l and creatinine of 53 µmol/l). Chromogranin A
level was elevated with a level of 139.50 ng/ml (normal refer-
ence range less than 101.9 ng/ml). Urine for sulfonylurea
screen was unavailable for testing. She also had mild normocy-
tic anaemia with a haemoglobin level of 11.3 g/l. Her CD4
count was 549 with a viral load that was suppressed on
highly active antiretroviral therapy for a duration of 6 years.
All other blood results were within normal reference limits.
In view of the history and findings the clinical impression
was that of an insulinoma.
To localise the insulinoma, an ultrasound of the abdomen
was done which did not find any masses. An abdominal con-
trast-enhanced computer tomography scan was performed
which showed a normal pancreas morphology with hom-
ogenous enhancement on all phases and no focal lesion.68
Ga-DOTA-octreotate PET/CT was performed, which showed
avid active disease in the uncinated process of the pancreas
with no evidence of nodal disease or distant metastasis
(Figures 1 and 2). Endoscopic ultrasound was also performed,
which revealed a well-visualised homogenously echoic pan-
creas with a well-circumscribed lesion with poor vascularity
visualised in the uncinated process measuring 1.5 by
1.4 cm. There was no evidence of local lymph node involve-
ment. Fine-needle aspiration was performed on the lesion.
Cytology revealed sheets of benign epithelial cells, occasional
pancreatic acinar cells and an isolated group of bland cells
with neuroendocrine features in keeping with a neuroendo-
crine tumour.
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Nerve conduction studies were also done, which indicated
decreased amplitude and increased latency suggestive of an
axonal neuropathy with secondary denervation.
Discussion
Insulinomas are rare functioning neuroendocrine tumours. They
occur in 1–4 per million per year.2 They are the most common
class of neuroendocrine tumours. They occur more commonly
in females, with an average age at presentation of 50 years.3
Insulinomas are commonly sporadic in nature. Less than 10%
are genetic in origin, associated with multiple endocrine neo-
plasia type 1 (MEN-1).3 MEN-1 is an autosomal-dominant syn-
drome affecting mainly the parathyroid glands, anterior
pituitary, endocrine pancreas and duodenum, due to inacti-
vation of the MEN1 gene on chromosome 11q13. Of the patients
with insulinoma associated with MEN1, the presentation is
earlier and female predominant 2. The majority of patients
with insulinomas present with hypoglycaemia in the fasting
state although it can also occur in the post-prandial state.3
Clinical presentation is due to hypoglycaemia, with adrenergic
symptoms and neuroglycopenic symptoms. Adrenergic
symptoms include palpitations, sweating and tremors. The
neuroglycopenic presentation varies per case ranging from con-
fusion to vague symptoms of weakness and objective hemipar-
esis/hemiplegia with symptoms dependent on the severity of
the hypoglycaemia.4
Neuroglycopenia as the main presenting complaint for hypogly-
caemia is uncommon, only described in case reports. However,
Table 1: Laboratory studies
Factor Results Reference range
Glucose (mmol/l) 1.3
Insulin (mIU/l) 23.8 2.6–24.9
C peptide (µg/l) 3 1.1–4.4
Chromogranin A (ng/ml) 139.50 < 101.9
Cortisol (nmol/l) 778 Morning 133–537
Afternoon 68–327 Figure 3: Glycaemic thresholds.
Figure 1: Ga-DOTA octreotate PET/CT showing avid active disease in the
uncinated process of the pancreas.
Figure 2: Enlarged Ga-DOTA octreotate PET/CT showing avid active
disease in the pancreas.
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on careful questioning they are present in more than 90% of
patients presenting with an insulinoma.5 As symptoms are
non-specific there is often a delay in diagnosis with an
average time of one year from onset of symptoms to final diag-
nosis with patients often misdiagnosed with neurological or psy-
chiatric disorders.5
It is well known that glucose is an obligate supplier of fuel to the
brain.6 The brain contains minimal glycogen stores and there-
fore relies on a consistent supply of glucose for normal function.
Counterregulatory hormones are in place to minimise reaching a
critical glucose level; these include suppression of insulin
secretion at a glucose level of about 4.5 mmol/l, increasing glu-
cagon when glucose level falls below 3.8 mmol/l, and cortisol,
growth hormone secretion and upregulation of the sympathetic
nervous system function are implemented when level reaches
below 3.0 mmol/l.7 Glycaemic thresholds at which these cou-
nter-regulatory mechanisms are implemented tend to be
lower in diabetic patients and patients with previous hypogly-
caemic episodes (see figure 3).6
Chronic hypoglycaemia can result in neurophysiological deterio-
ration in patients with insulinoma with delayed recovery when
hypoglycaemia is missed or not rapidly corrected as in this case.8
Peripheral neuropathy as a main presenting complaint in
patients with insulinoma is rare, and only described in case
reports. It is usually a complication of chronic hypoglycaemia
rather than hyperinsulinemia itself.9 The type of neuropathy is
usually axonal in nature with both sensory and motor nerves
involved. Usually the sensory symptoms recover after removal
of the tumour whereas the motor symptoms may persist.9 Sei-
zures are a great mimicker of insulinomas, often misdiagnosed
as a primary seizure disorder with electroencephalography find-
ings compatible with epilepsy.
Neurocognitive disorders are common in patients with HIV,
occurring in almost half of patients, even in those who are
virally suppressed.10 These are related to the virus itself, second-
ary infections and drug therapies. The presence of this factors
might have contributed to the clinical presentation and delay
in diagnosis. Neuroendocrine tumours are very rare in HIV-
positive patients with only a few case reports published in the
literature.
Diagnosis of an insulinoma is based on demonstration of excess
endogenous insulin secretion in the setting of hypoglycaemia.
Often a 72-hour fast is required to confirm the diagnosis by pro-
voking homeostatic responses in the setting of no caloric intake.
The use of biomarkers such as a chromogranin A for diagnostic
purposes is not reliable as values maybe be normal in the pres-
ence of disease.11
Localisation of the tumour is often a challenge as the majority of
insulinomas are small in size and often less than 2 cm. The
imaging of choice is still contentious. Often invasive investi-
gations have to be performed in order to localise the tumour.
Diagnostic options range from transabdominal ultrasonography
to computer tomography, magnetic resonance imaging and
nuclear imaging, with MRI having the highest specificity and
sensitivity but cost being the limiting factor.12 Transoesophageal
endoscopic ultrasonography (TEE) may also be required if the
tumour cannot be visualised on imaging.
The treatment of choice in insulinomas is surgical exploration.
Medical therapy to manage symptomatic hypoglycaemia is an
option for use perioperatively or in a patient who is not a surgi-
cal candidate. Medical therapy includes diazoxide (which inhi-
bits insulin secretion) and somatostatin analogues.
This case ended tragically. Unfortunately, because of her severe
neurological complications, the patient died prior to any surgical
intervention.
Conclusion
Insulinoma is a rare neuroendocrine tumour. Diagnosis is often
delayed and can result in lasting neurological complications.
Clinicians must always have a higher suspicion of insulinoma
in a patient with hypoglycaemia. Investigations need to be expe-
dited to prevent non-reversible neurological consequences of
chronic hypoglycaemia.
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